Search Results

Business

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

Attralus, Inc. and Ossianix announced today that they have entered into a definitive agreement using Ossianix’ brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease.

November 17, 2022

·

4 min read

Drug Development

Ossianix Announces Publication of Positive Preclinical Data on Neutralizing SARS-CoV-2 Infection with a Panel of Single Domain Shark VNAR Antibodies

Ossianix, an antibody engineering company, and the University of Graz today announced the publication of a preclinical study that describes discovery of highly potent neutralizing single domain shark antibodies (VNARs) directed against the SARS-CoV-2 spike protein.

June 10, 2021

·

2 min read

Drug Development

CORRECTION: Ossianix Announces Publication of Positive Preclinical Data on Neutralizing SARS-CoV-2 Infection with a Panel of Single Domain Shark VNAR Antibodies

Ossianix, an antibody engineering company, and the University of Graz announced the publication of a preclinical study that describes discovery of highly potent neutralizing single domain shark antibodies directed against the SARS-CoV-2 spike protein.

June 10, 2021

·

3 min read

Drug Development

Ossianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies

Ossianix, an antibody engineering company, announced the results of a non-human primate study demonstrating best-in-class blood-brain barrier delivery by single domain antibodies.

November 9, 2020

·

2 min read

Business

Ossianix and Novo Nordisk Sign Research and Option Agreement on Blood Brain Barrier Delivery Technology for Proteins in Diabetes and Other Metabolic Diseases

Ossianix, Inc. today announced a research collaboration and option agreement with Novo Nordisk to deliver therapeutic molecules in diabetes and other metabolic diseases across the Blood Brain Barrier (BBB) to the brain.

September 4, 2018

·

2 min read

Business

Ossianix Release: Company Receives Milestone Payment From H. Lundbeck A/S For Blood-Brain Barrier (BBB) Antibody Delivery Technology

January 26, 2017

·

3 min read

Business

Ossianix Announces Strategic Research Collaboration With Lundbeck Inc.

January 7, 2014

·

1 min read

Business

Ossianix Expands And Extends Its Research Collaboration With H. Lundbeck A/S On CNS Therapeutics

December 16, 2014

·

4 min read

Pharm Country

Ossianix Announces Lundbeck Inc. Investment

January 3, 2012

·

1 min read

Business

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of DirectorsTwo highly experienced industry executives who bring a wealth of leadership and drug development experience

NovalGen Ltd, a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.

January 9, 2023

·

3 min read